Beijer Alma to present Q3 interim report in webcast and conference call
Bitget2026/10/09 11:01Beijer Alma will publish its Q3 2026 interim report on Oct. 23, 2026 at about 08:00 CEST. Management will present the results in a webcast on Oct. 23, 2026 at 10:00 CEST via https://events.inderes.com/beijer-alma/q3-report-2026. A conference call is scheduled for Oct. 23, 2026 at 10:00 CEST via https://events.inderes.com/beijer-alma/q3-report-2026/dial-in. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beijer Alma AB published the original content used to generate this news brief on October 09, 2026, and is solely responsible for the information contained therein.
- Beijer Alma will publish its Q3 2026 interim report on Oct. 23, 2026 at about 08:00 CEST.
- Management will present the results in a webcast on Oct. 23, 2026 at 10:00 CEST via https://events.inderes.com/beijer-alma/q3-report-2026.
- A conference call is scheduled for Oct. 23, 2026 at 10:00 CEST via https://events.inderes.com/beijer-alma/q3-report-2026/dial-in.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Blackstone (BX.US) injects up to $1.5 billion, providing fresh ammunition for Pfizer (PFE.US) in the weight-loss drug race
Pfizer announced on Wednesday that it has reached an agreement with Blackstone to obtain up to $1.5 billions in funding to support the development of its experimental monthly obesity treatment drug.
Bernstein Downgrades Nvidia Rating and Target Price

Google (GOOGL.US) DeepMind launches AlphaGenome 2: Capable of decoding DNA cells with nearly double the mutation identification capacity
Google DeepMind has released its AI model AlphaGenome 2, which is trained on maps of over 100 millions of cells and has nearly double the ability of its predecessor in identifying gene expression variations.
